The deal adds two marketed, patent-protected, high-margin non-opioid pain therapiesβEXPAREL and ZILRETTAβto Viatris' portfolio and is expected to clo...
π Free alerts β https://gunpowderalerts.com/go?utm_source=bluesky&utm_medium=social&utm_campaign=high_priority_filing
#WallStreet #SECfilings #8K
